LEO Pharma and Elektrofi expand partnership to co-develop new antibodies with the aim of achieving improvements in drug delivery within dermatology
Ballerup, April 9, 2019: LEO Pharma A/S, a global leader in medical dermatology and Elektrofi, a Boston- based biotechnology company focused on drug formulation and delivery innovations, today announced an expansion of the two companies’ partnership agreement (signed in 2017) to further include antibodies from LEO Pharma’s pipeline with the aim of achieving improvements in drug delivery within dermatology.
As part of the agreement LEO Pharma and Elektrofi will initially co-develop two specific anti-bodies. The agreement includes an option to a pre-negotiated license for the potentially improved antibodies in the pre-clinical and clinical stage. LEO Pharma and Elektrofi will work closely together in an alliance to enable a lower injection volume for subcutaneous administration and, in turn, enable novel formulations and better convenience for patients.
“At LEO Pharma we are working constantly to find innovative ways to help people with skin diseases and improve their quality of life. Together with Elektrofi, we hope to find new, more convenient solutions for drug delivery, which potentially will be of benefit to patients,” said Kim Kjøller, executive Vice President, Research & Development, LEO Pharma.
“We are excited to further our partnership with LEO Pharma, who we consider to be a leader in patient centric innovation. This flagship deal for our growing company is an exciting consummation of a close partnership over the last 2 years. The biopharma industry’s continued shift to subcutaneous administration is a reflection of patients’ demand for convenience. Elektrofi is thrilled to utilize its technology with LEO Pharma to improve patients’ lives,” said Jason Norris, Cofounder, Elektrofi.
About Elektrofi’s technology: Elektrofi leverages its microparticle suspension formulation technology (ElektrojectTM) to enable syringe-compatible injections of high-dose antibody therapeutics. Most antibody solutions are unusable in syringes at high concentrations due to concentration associated syringe forces that exceed human ability, leaving drug developers to either increase dose frequency or administer prolonged, large-volume infusions. ElektrojectTM suspensions enable clinicians and patients to administer high doses of antibody therapies in a relatively small volume within seconds in addition to providing improved product stability at full quality.
Jason Norris, Cofounder
LEO Pharma A/S
Trine Juul Wengel
Tel.: +45 20732037
Information om LEO Pharma
Elektrofi is a biotechnology company headquartered in Boston, MA, USA working on transforming the delivery of biologics. We envision a patient-centric future where all protein therapeutics can be conveniently administered to patients in small-volume syringe injections instead of large-volume intravenous infusions or frequent injections. Elektrofi’s gentle platform technology, ElektrojectTM, enables the transformation to high-dose subcutaneous delivery without compromise on product quality for a wide-range of biologics. For more information, please visit www.elektrofi.com or send a message to
About LEO Pharma
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 5,500 people, serving 76 million patients in 130 countries. In 2018, the company generated net sales of DKK 10,410 million.
For more information, go to: www.linkedin.com/company/leo-pharma or www.leo-pharma.com
Følg pressemeddelelser fra LEO Pharma
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra LEO Pharma
LEO Pharma udnævner Catherine Mazzacco som ny CEO3.6.2019 09:00:00 CEST | Pressemeddelelse
Ballerup, den 3. juni 2019. LEO Pharma offentliggjorde i dag, at Gitte Aabo efter 27 år i virksomheden – og heraf de seneste 11 som adm. direktør – træder tilbage fra posten som øverste chef den 31. juli 2019. Bestyrelsen har udpeget Catherine Maz-zacco som ny adm. direktør med tiltrædelse 1. august.
LEO Pharma Strengthens US footprint and Global Development Team with appointment of Vice Presidents for Global Regulatory Affairs and Global Project Management10.5.2019 10:27:35 CEST | Pressemeddelelse
Ballerup, Denmark, May 10, 2019 – LEO Pharma A/S, a global leader in medical dermatology, today announced the appointment of Beth-Anne Lang, Vice President and Head of Global Regulatory Affairs and Christine Garrett, Vice President and Head of Global Project Manage-ment. Both will join LEO Pharma on May 13.
New General Manager appointed to lead LEO Pharma across the Nordic region1.5.2019 10:12:37 CEST | Pressemeddelelse
Klaus Abel arrives to take the regional helm of the global medical dermatology leader
New data show that LEO Pharma’s Kyntheum® (brodalumab) sustains PASI 100 scores longer than ustekinumab for people with moderate-to-severe plaque psoriasis25.4.2019 09:12:24 CEST | Pressemeddelelse
Ballerup, Denmark, April 25, 2019: LEO Pharma A/S, a global leader in medical dermatology, today announced that new data presented this week at the 6th Congress of the Skin Inflammation and Psoriasis International Network (SPIN) in Paris demonstrate that more patients with moderate-to-severe psoriasis who received treatment with brodalumab maintained a PASI (Psoriasis Area Severity Index) 100 score for longer than those who were treated with ustekinumab over 52 weeks.
LEO Pharma and Research Project BIOMAP: Towards Personalised Medicine for Inflammatory Skin Diseases11.4.2019 11:40:51 CEST | Pressemeddelelse
The large-scale IMI project will investigate the causes and mechanisms of Atopic Dermatitis and Psoriasis
LEO Pharma A/S and LTS Lohmann Therapie-Systeme AG initiate first-ever clinical trial of microarray patches for psoriasis treatment19.3.2019 10:33:23 CET | Pressemeddelelse
Andernach, DE, and Ballerup, DK, March 19, 2019: LTS Lohmann Therapie-Systeme AG (LTS), a market leader in transdermal therapeutic systems, and LEO Pharma A/S, a global leader in dermatology, today announced that the companies will start the clinical trial of microarray patches for the local intradermal treatment of psoriasis. The study will start in April 2019 with expected completion later this year and the aim of the study is to document safety and efficacy in patients.
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum